Gonadal Function Recovery in Patients With Advanced Hodgkin Lymphoma Treated With a PET-Adapted Regimen: Prospective Analysis of a Randomized Phase III Trial (AHL2011)

Cost-effectiveness of first-line treatment options for patients with advanced-stage Hodgkin lymphoma: a modelling study

(2020) Abi Vijenthira et al.   Lancet Haematology

Long‐term overall survival and toxicities of ABVD vs BEACOPP in advanced Hodgkin lymphoma: A pooled analysis of four randomized trials

(2020) Marc P. E. André et al.   Cancer Medicine

Fertility preservation and post-treatment pregnancies in post-pubertal cancer patients: ESMO Clinical Practice Guidelines

(2020) M. Lambertini et al.   ANNALS OF ONCOLOGY

ABVD and BEACOPP regimens’ effects on fertility in young males with Hodgkin lymphoma

(2020) M. S. A. Amin et al.   Clinical & Translational Oncology

Cancer survivorship: Reproductive health outcomes should be included in standard toxicity assessments

(2020) Richard A. Anderson et al.   EUROPEAN JOURNAL OF CANCER

PET-adapted treatment for newly diagnosed advanced Hodgkin lymphoma (AHL2011): a randomised, multicentre, non-inferiority, phase 3 study

(2019) René-Olivier Casasnovas et al.   LANCET ONCOLOGY

Anti-Müllerian hormone levels and incidence of early natural menopause in a prospective study

(2018) Elizabeth R Bertone-Johnson et al.   HUMAN REPRODUCTION

Determinants of ovarian function after response-adapted therapy in patients with advanced Hodgkin's lymphoma (RATHL): a secondary analysis of a randomised phase 3 trial

(2018) Richard A Anderson et al.   LANCET ONCOLOGY

Another step towards improving oncofertility counselling of young women with Hodgkin's lymphoma

(2018) Matteo Lambertini et al.   LANCET ONCOLOGY

Anti-Müllerian hormone as a predictor of reproductive potential

(2018) Leah Hawkins Bressler et al.   Current Opinion in Endocrinology Diabetes and Obesity

ESHRE Guideline: management of women with premature ovarian insufficiency

(2016)   HUMAN REPRODUCTION

No Evidence for the Benefit of Gonadotropin-Releasing Hormone Agonist in Preserving Ovarian Function and Fertility in Lymphoma Survivors Treated With Chemotherapy: Final Long-Term Report of a Prospective Randomized Trial

(2016) Isabelle Demeestere et al.   JOURNAL OF CLINICAL ONCOLOGY

Assisted reproductive outcomes of male cancer survivors

(2014) Ainhoa García et al.   Journal of Cancer Survivorship

Fertility and gonadal function in female survivors after treatment of early unfavorable Hodgkin lymphoma (HL) within the German Hodgkin Study Group HD14 trial

(2012) K. Behringer et al.   ANNALS OF ONCOLOGY

Gonadal Function and Fertility in Survivors After Hodgkin Lymphoma Treatment Within the German Hodgkin Study Group HD13 to HD15 Trials

(2012) Karolin Behringer et al.   JOURNAL OF CLINICAL ONCOLOGY

Pretreatment Serum Anti-Müllerian Hormone Predicts Long-Term Ovarian Function and Bone Mass after Chemotherapy for Early Breast Cancer

(2011) Richard A. Anderson et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Escalated-Dose BEACOPP in the Treatment of Patients With Advanced-Stage Hodgkin's Lymphoma: 10 Years of Follow-Up of the GHSG HD9 Study

(2009) Andreas Engert et al.   JOURNAL OF CLINICAL ONCOLOGY

Anti-Müllerian hormone follow-up in young women treated by chemotherapy for lymphoma: preliminary results

(2009) Christine Decanter et al.   REPRODUCTIVE BIOMEDICINE ONLINE